Lead sponsor
GlyPharma Therapeutics
3 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of November 5, 2026.
3
Trials led
0
Ongoing
16
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1/2
3
Trials by status
Completed
2
Withdrawn
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal InsufficiencyBMI 16-32Ph 1/2Completed8
Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral SupportBMI 16-32Ph 1/2Completed8
Safety, Tolerability, PK/PD of FE 203799 in Adults With LymphomasEF ≥50%Ph 1/2Withdrawnnot disclosed